NSE: SUVENPHAR | BSE: 543064

Expensive Performer

Download real time

1081.70 28.45 (2.70%)

80.89% Gain from 52W Low

217.9K NSE+BSE Volume

NSE 08 Apr, 2025 3:31 PM (IST)

Broker 1Year buys

2 active buys

Broker 1Year sells

0 active sells

Broker 1Year neutral

0 active holds

Analyst Buy

Goldman Sachs initiates a 'Buy' rating on Suven Pharma; sets a target price of Rs 1,350 See details

Suven Pharmaceuticals Ltd. share price target

Name: Latest research reports of Suven Pharmaceuticals Ltd. authored by Anand Rathi and published by - Trendlyne research reports.
Item: Suven Pharmaceuticals Ltd.
Rating: 5
Author: Anand Rathi

Suven Pharmaceuticals Ltd. has an average target of 1402.50. The consensus estimate represents an upside of 29.66% from the last price of 1081.70. View 2 reports from 2 analysts offering long-term price targets for Suven Pharmaceuticals Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
08 Apr 2025	Suven Pharma	Consensus Share Price Target	1081.70	1396.67	-	29.12	buy	pdf Detailed Estimates
18 Aug 2020	Suven Pharma	Anand Rathi	1081.70	760.00	678.15 (59.51%)	Target met	Buy	pdf post cache	Broker Report Suven Pharma Anand Rathi Valuation. At the CMP of `652, the stock trades at 22.1x, 18.3x and 15.5x respective FY21e/22e/23e earnings. We retain our Buy recommendation, with a higher price target of `760 (earlier `695), based on 18x FY23e EPS. Risks:... pdf Copy Link Share on Share on Share on Share on Alert
02 Jul 2020	Suven Pharma	Geojit BNP Paribas	1081.70	587.00	508.05 (112.91%)	Target met	Buy	pdf post cache	Broker Report SUVEN PHARMACEUTICALS LIMITED Geojit BNP Paribas During the year total revenues grew by 27% to Rs.834crs driven by 18% growth in CRAMS, 41% growth in Speciality chemicals and 40% growth in Formulations. In the CRAMS segment, the company has been able to add new customers during the year and the segment is now 56% of total revenues. In the coming year, the management stated that new projects may be difficult to undertake owing to the ongoing Covid-19 scenario. In CRAMS, the company plans to integrate into APIs and later into formulations, in addition to intermediates, which it is currently focusing on. We expect a revenue CAGR of 13% for CRAMS over FY20-FY22E... pdf Copy Link Share on Share on Share on Share on Alert

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

80.89% Gain from 52W Low

Suven Pharmaceuticals Ltd. share price target

Suven Pharmaceuticals Ltd. has an average target of 1402.50. The consensus estimate represents an upside of 29.66% from the last price of 1081.70. View 2 reports from 2 analysts offering long-term price targets for Suven Pharmaceuticals Ltd..

Suven Pharma

SUVEN PHARMACEUTICALS LIMITED

Advisor Screeners